US2015182672A1PendingUtilityA1

Coatings for implantable medical devices

Assignee: ABBOTT CARDIOVASCULAR SYSTEMSPriority: Mar 20, 2002Filed: Mar 10, 2015Published: Jul 2, 2015
Est. expiryMar 20, 2022(expired)· nominal 20-yr term from priority
A61L 2300/606A61L 31/10A61L 31/16A61L 2300/43A61L 2300/416C08G 18/711C08F 2810/50C08F 8/00C09D 175/04C09D 151/08C08F 2800/10A61K 31/4745A61K 31/337C09D 151/003C08G 18/6212A61K 31/56C08F 8/32C08F 8/30C09D 151/06
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application teaches a coating having a biologically compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit and at least one unit derived from a vinyl alcohol, an allyl alcohol, or derivatives thereof.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A coating for a medical device, wherein the coating comprises:
 a biologically compatible compound blended with a polymer, wherein the polymer comprises
 at least one unit (I)
   —CH 2 —CH 2 —  (I)
 
 
 and at least one unit (II) 
   
       
         
           
           
               
               
           
         
       
       wherein,
 R 1  comprises a component selected from a group consisting of a carboxy, an ester, an ether, an amide, a urethane, an amine, a toluenesulfoester, a 2,2,2-trifluoroethylsulfoester, an epoxy, and a glycidyl group; and 
 R 2  comprises a component selected from a group consisting of a hydrogen and an alkyl group. 
 
     
     
         2 . The coating of  claim 1 , wherein the polymer comprises: 
       
         
           
           
               
               
           
         
       
       wherein,
 R 1  comprises a component selected from a group consisting of a carboxy, an ester, an ether, an amide, a urethane, an amine, a toluenesulfoester, a 2,2,2-trifluoroethylsulfoester, an epoxy, and a glycidyl group; 
 R 2  comprises a component selected from a group consisting of a hydrogen and an alkyl group; 
 the molecular weight of R 1  or R 2  ranges from about 1 to about 30,000 Daltons; and, 
 the total of m+n is an integer ranging from about 50 to about 7,000. 
 
     
     
         3 . The coating of  claim 1 , wherein the molecular weight of R 1  or R 2  ranges from about 1 to about 30,000 Daltons; and, the total of m+n is an integer ranging from about 50 to about 7,000. 
     
     
         4 . The coating of  claim 1 , wherein the molecular weight of R 1  is about 5000 Daltons. 
     
     
         5 . The coating of  claim 1 , wherein the alkyl is methyl. 
     
     
         6 . The coating of  claim 1 , wherein the polymer comprises 
       
         
           
           
               
               
           
         
       
       and,
 the total of m+n is an integer ranging from about 50 to about 7,000. 
 
     
     
         7 . The coating of  claim 1 , wherein the biologically compatible compound comprises a poly(alkylene glycol), a poly(alkylene glycol) derivative, a protein, a polysaccharide, a superoxide dismutase mimetic, a diazenium diolate, or a combination thereof. 
     
     
         8 . The coating of  claim 1 , wherein the biologically compatible compound comprises poly(ethylene glycol). 
     
     
         9 . The coating of  claim 1 , wherein the biologically compatible compound is conjugated to a protein or to a polysaccharide. 
     
     
         10 . The coating of  claim 9 , wherein the protein comprises albumin. 
     
     
         11 . The coating of  claim 9 , wherein the polysaccharide comprises a component selected from a group consisting of hyaluronic acid, heparin, heparin derivatives containing a hydrophobic counter-ion and chitosan. 
     
     
         12 . The coating of  claim 7 , wherein the diazenium diolate comprises a component selected from a group consisting of 1,3-propanediamine, N-{4-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino]butyl}-diazen-1-ium-1,2-diolate and 1-{N-methyl-N-[6-(N-methylammonio)hexyl]amino}diazen-1-ium-1,2-diolate. 
     
     
         13 . The coating of  claim 7 , wherein the superoxide dismutase mimetic comprises manganese(II)dichloro-aminoethylthiolated pentaazatetracyclohexacosatriene. 
     
     
         14 . The coating of  claim 1 , further comprising a therapeutic substance. 
     
     
         15 . The coating of  claim 14 , wherein the therapeutic substance comprises actinomycin D, estradiol, paclitaxel, docetaxel, or rapamycin. 
     
     
         16 . The coating of  claim 1 , wherein the medical device comprises a stent.

Join the waitlist — get patent alerts

Track US2015182672A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.